Thrive Bioscience (thrivebio.com) is commercializing a family of high-end, capital instruments and software tools that provide imaging, analytics, and automation for reproducible cell culture. Thrive’s instruments significantly improve cell culture workflows, and the analysis of live cells in research and bioprocessing. As a result, biologists are empowered to deliver reproducible results by leveraging microscopy, robotics, and fluidics to capture images and data, which provide analysis, guidance, documentation, and a database of cells. The principal markets are drug discovery, drug development, regenerative medicine, basic research, and the delivery of cell therapeutics.
Thrive Bioscience launched the CellAssist in December 2019, a bench-top instrument optimized for collecting and analyzing live cells, to pharmaceutical companies and research institutes. In late 2020, the company will begin delivery of the AutoImager, which combines the CellAssist along with a 50-plate automated incubator. The company was founded in 2014, has a portfolio of 53 patent applications, of which eight have been issued, and today collaborates with several leading academic institutions.